Conference Coverage
Conference Coverage
Sepsis’ readmission costs dwarf heart attack, heart failure costs
Sepsis-related hospital readmission costs in California adults were more than double those for congestive heart failure and more than triple those...
Conference Coverage
Diabetes educators enhance care, improve outcomes in the primary care settings
Integrating diabetes education into primary care using certified diabetes educators is feasible and effective for improving outcomes.
Conference Coverage
Erosive hand disease likely ‘more severe form of OA’
Erosive hand osteoarthritis is probably a more severe form of the disease, rather than a separate clinical entity, a team of Norwegian researchers...
Conference Coverage
WCD: Dapsone gel effective for acne in women of color
Dapsone gel 5% is effective and well-tolerated for treatment of facial acne in women with skin of color.
Conference Coverage
Depression, stress don’t predict outcomes in recurrent pregnancy loss
Depression and emotional stress did not lead to poorer pregnancy outcomes 1-year after referral for recurrent pregnancy loss in a prospective,...
Conference Coverage
EULAR: Intra-articular Traumeel and Zeel injections offer ‘favorable’ knee OA pain relief
Key clinical point: The degree of pain control achieved with the homeopathic product combination was consistent with that seen with other injected...
Conference Coverage
EULAR: Steroid injection accuracy may not matter for OA knee pain relief
Key clinical point: Reductions in pain achieved with intra-articular corticosteroid injections were not influenced by the accuracy of injection....
Conference Coverage
WCD: Topical tofacitinib hits marks in atopic dermatitis
Topical tofacitinib, a Janus kinase inhibitor, may provide a novel safe and effective therapy for atopic dermatitis.
Conference Coverage
AHS: Noncephalic pain sites shed light on progression from episodic to chronic migraine
Location of noncephalic pain site, as well as the number of them, the frequency of pain, and intensity of pain, are useful indicators of the...
Conference Coverage
High VTE recurrence risk persists for at least 3 years
The risk of recurrence following an initial episode of venous thromboembolism is highest in the first 3 months, but remains high for up to 3 years...
Conference Coverage
Statins showed no benefit in reducing risk of recurrent VTE
The use of statins showed no benefit in reducing the risk of recurrent venous thromboembolism in patients enrolled in phase III trials comparing...